A Phase II Trial of Postoperative Chemotherapy Plus Adjuvant and Maintenance Bevacizumab After Neoadjuvant Chemotherapy Followed by Interval Surgery in Patients With Extensive Stage IIIC or IV Ovarian, Tubal, and Peritoneal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 27 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 27 Oct 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.
- 08 Jan 2014 New trial record